Clinical trial
A Prospective, Multi-Center, Randomized Control Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
NCT01967875 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective, Multi-Center, Randomized Control Phase 2 Trial of Optimizing Platinum-Based Chemotherapy Based on ERCC1 Expression as First-Line Treatment in Patients With Locally Advanced or Metastatic Gastric Cancer
- Lead sponsor
- China Medical University, China
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 31, 2013
- Completion date
- May 31, 2016
- Enrollment
- 27 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.